• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/5/25 6:15:01 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    hsic-20250805
    0001000228 false NASDAQ 0001000228 2025-08-05 2025-08-05
     
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON,
     
    D.C. 20549
    FORM
    8-K
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported):
    August 5, 2025
    Henry Schein, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction
    of incorporation)
     
    0-27078
    (Commission
    File Number)
     
    11-3136595
    (IRS Employer
    Identification No.)
     
     
     
     
     
    135 Duryea Road
    ,
    Melville
    ,
    New York
    (Address of principal executive offices)
    11747
    (Zip Code)
    Registrant’s telephone number, including area code: (
    631
    )
    843-5500
    (Former name or former address, if changed since last
     
    report.)
    Check the appropriate box
     
    below if the
     
    Form 8-K filing is intended to simultaneously satisfy
     
    the filing obligation of
     
    the registrant under any
     
    of the following
    provisions:
    ☐
     
    Written communications pursuant
     
    to Rule 425
     
    under the Securities
     
    Act (17 CFR 230.425)
    ☐
     
    Soliciting material pursuant to
     
    Rule 14a-12 under
     
    the Exchange Act (17
     
    CFR 240.14a-12)
    ☐
     
    Pre-commencement communications pursuant to
     
    Rule 14d-2(b) under
     
    the Exchange Act
     
    (17 CFR 240.14d-2(b))
    ☐
     
    Pre-commencement communications pursuant to
     
    Rule 13e-4(c) under the
     
    Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to
     
    Section 12(b) of the
     
    Act:
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $.01 per share
     
    HSIC
     
    The
    Nasdaq
     
    Global Select Market
    Indicate by check mark whether the registrant is an emerging growth
     
    company as defined in Rule 405 of the Securities Act
     
    of 1933 (§230.405 of this chapter) or Rule
    12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
     
    of this chapter).
    Emerging growth company
     
    ☐
    If an emerging growth company,
     
    indicate by check mark if the registrant has
     
    elected not to use the extended transition period
     
    for complying with any new or revised
    financial accounting standards provided pursuant to Section 13(a) of
     
    the Exchange Act.
     
    ☐
     
    Item 2.02.
     
    Results of Operations and Financial Condition.
    On August 5, 2025, Henry Schein, Inc. issued a press release reporting
     
    the financial results for the three and six
    months ended June 28, 2025.
     
    The full text of the press release is attached hereto as Exhibit
     
    99.1 and is incorporated
    herein by reference.
    The information in this Item 2.02 and the press release attached as Exhibit
     
    99.1 are considered furnished to the
    Securities and Exchange Commission and are not deemed filed for purposes
     
    of Section 18 of the Securities Exchange
    Act of 1934, as amended.
    Item 9.01.
     
    Financial Statements and Exhibits
    (a)
     
    Not applicable.
    (b)
     
    Not applicable.
    (c)
     
    Not applicable.
    (d)
     
    Exhibit 99.1 – Press Release dated August 5, 2025.
    Exhibit 104 - Cover Page Interactive Data File (embedded within the
     
    Inline XBRL document)
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the
     
    registrant has duly caused this report to
    be signed on its behalf by the undersigned hereunto duly authorized.
    HENRY SCHEIN, INC.
    By:
    /s/ Ronald N. South
    Ronald N. South
    Senior Vice President and
    Chief Financial Officer
    (Authorized Signatory and Principal
    Financial and Accounting Officer)
    August 5, 2025
    EXHIBIT INDEX
    Exhibit No.
    Description
    99.1
    Press Release dated August 5, 2025.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL
     
    document)
    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Kkr Hawaii Holdings L.P. claimed ownership of 15,263,662 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/15/25 9:30:38 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 7:00:45 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 1,650 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.51% to 322,097 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/14/25 4:50:03 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein One Launches Forms to Make Patient Check-In Easier and Faster

    With a native end-to-end workflow in Dentrix and Dentrix Ascend, the new Forms cuts manual work and extra logins for a smoother start to every visit Henry Schein One, the most connected solution in dental technology, today launched Forms for Dentrix and Dentrix Ascend (Ascend). With more than 1,000 dental practices adopting Forms just this month, this fully integrated digital intake solution is already simplifying the pre-appointment process for both patients and dental teams. With mobile-friendly and customizable forms, ID and insurance card scanning, and secure two-factor authentication, Forms makes patient check-in virtually touchless. And early results show that 90% of patients comple

    7/30/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

    7/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 10-Q filed by Henry Schein Inc.

    10-Q - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 3:03:18 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    8/5/25 6:15:01 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    7/15/25 7:10:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00

    7/14/25 8:40:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on Henry Schein with a new price target

    Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

    2/14/25 7:05:26 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Second Quarter 2025 Financial Results

    Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June

    8/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2025 financial results before the stock market opens on Tuesday, August 5, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available

    7/22/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2025 Financial Results

    First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

    5/5/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care